zolbetuximab

01/01/2023 - "In recent years, several important trials have been published showing that zolbetuximab is associated with improved prognosis in patients with advanced gastric or gastro-esophageal junction (G/GEJ) adenocarcinoma. "
05/01/2021 - "Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma."
01/01/2023 - "Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma."
04/01/2023 - "Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma."
01/01/2023 - "Background: The SPOTLIGHT trial demonstrated that zolbetuximab plus mFOLFOX6 (ZOL-FO) as a first-line regimen compared with placebo plus mFOLFOX6 (PLB-FO) conferred clinical benefits to patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. "

01/01/2018 - "Findings from this study demonstrate that IMAB362 is generally well tolerated and support further evaluation in patients with gastric/gastro-oesophageal junction cancer. "
10/02/2023 - "These data support the first-line development of zolbetuximab in patients whose tumors are CLDN18.2-positive. "
08/01/2023 - "Zolbetuximab mediates proficient ADCC in patients with pretreated advanced G/GEJ cancers. "
02/01/2023 - "In in vivo assays, IMAB362-mIL-21 produced stronger anti-tumor effects compared with IMAB362 or mIL-21 or their combination at equimolar concentrations. "
01/01/2019 - "Zolbetuximab monotherapy was well tolerated and exhibited antitumour activity in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinomas, with response rates similar to those reported for single-agent targeted agents in gastric/GEJ cancer trials. "

01/01/2023 - "Zolbetuximab treatment in metastatic gastric cancer."
01/01/2023 - "Zolbetuximab Improves Survival in Gastric Cancer."
11/01/2023 - "Zolbetuximab in metastatic gastric cancer will emerge as a new therapy option."
12/01/2017 - "This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer."
01/01/2016 - "Results from a randomized phase II study indicate that adding the experimental antibody IMAB362, which targets the tight junction protein claudin18.2, to standard chemotherapy is more effective than chemotherapy alone in previously untreated patients with advanced gastric cancer. "

01/01/2023 - "Zolbetuximab treatment showed a significant reduction in the risk of disease progression or death compared with placebo (hazard ratio [HR] 0·75, 95% CI 0·60-0·94; p=0·0066). "
05/01/2021 - "Patients could receive ≤ 8 EOX cycles and remained on zolbetuximab until disease progression. "

01/01/2019 - "In mouse xenograft tumors derived from human PC cell lines, including gemcitabine-refractory ones, zolbetuximab slowed tumor growth, benefited survival, and attenuated metastases development. "
12/01/2017 - "Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. "